Pearl Therapeutics Highlights Its Porous Particle Cosuspension Platform, Demonstrating Universal Applicability Across Multiple Drug Classes and Combination Products

Bio-Medicine.Org

REDWOOD CITY, Calif., May 5, 2011 /PRNewswire/ -- Pearl Therapeutics Inc. made three presentations at the Respiratory Drug Delivery Europe (RDD Europe 2011) meeting in Berlin this week elucidating the tunability, versatility and universality of the Company's porous particle-based metered dose inhaler (MDI) development approach. The data provides details of Pearl's products and novel cosuspension platform [1], which facilitates forming stable MDI suspensions containing respiratory drugs as single components at various doses, various dual combinations, and a highly uniform triple drug combination. Further, Pearl's technology accommodates drugs of different pharmacological and chemical classes and uses conventional manufacturing processes for clinical and commercial scale production.

"Pearl scientists have developed a novel and unique cosuspension formulation approach that allows different respiratory medicines and their combinations to be formulated readily, and delivered efficiently, with the simple press-and-breathe MDI dosage form," commented Sarvajna Dwivedi [2], Ph.D., executive vice president and cofounder of Pearl Therapeutics. "Utilizing commercially available MDI components and manufacturing equipment, we have rapidly progressed two highly potent bronchodilators, both alone and as a dual combination product, into Phase 2b development, while successfully formulating a triple drug combination in parallel, with extensive proof of stability for each product. Our progress and results show that the cosuspension platform has the potential of formulating drug products for improved predictability of clinical development, enhanced patient experience and compliance across therapy types, and reduced development and manufacturing costs."

In his oral presentation, Dr. Dwivedi described the physicochemical characteristics '/>"/>

SOURCE [3]

Source URL (retrieved on *07/28/2014 - 8:54am*):
http://www.mdtmag.com/news/2011/05/pearl-therapeutics-highlights-its-porous-particle-cosuspension-platform-demonstrating-universal-applicability-across-multiple-drug-classes-and-combination-products?qt-video_of_the_day=0

Links:

[1] http://pearltherapeutics.com/proprietary-platform-technology
[2] http://pearltherapeutics.com/management-team
[3] http://www.bio-medicine.org/medicine-technology-1/Pearl-Therapeutics-Highlights-Its-Porous-Particle-Cosuspension-Platform--Demonstrating-Universal-Applicability-Across-Multiple-Drug-Classes-and-Combin-16976-1/